08045804815

TABNCAP HEALTHCARE
GST : 24AAMFT3098D1Z1

Our Products

Ophthalmic Diagnostic Test Strips

Intraocular Lenses

Contact Lenses

Ophthalmic Solutions and Viscoelastics

Vitreoretinal Products

Ophthalmic Machine

Hyaluronic Acid Gel for Dremel

Hyaluronic Acid Gel for Dremel

Absorbable Hemostatic Gelatin Sponge And Powder

Natural Colors Contact Lens

Home Care Products

Skin Care Products

Bryxta 400 Mg Injection

Bryxta 400 Mg Injection Specification

Usage Type
Hospital, Clinical

Storage Instructions
Store between 2C-8C, Do Not Freeze

Features
Ready to Use, Sterile, Preservative Free

Instruments Type
Therapeutic Injection

Function
Anti-Cancer Agent, Monoclonal Antibody

Shelf Life
24 Months

Equipment Type
Pharmaceutical Injection

Material
Sterile Solution

Condition
New

Technology
Biotechnology (Monoclonal Antibody)

Portable
Yes (in Single-Use Vial)

Wall Mounted
No

Operating Type
Parenteral (Intravenous Use)

Use
Cancer Treatment

Color
Transparent/Colorless

Dosage Form
Injection

Appearance
Clear, colorless to pale yellow solution

Generic Name
Bevacizumab

Contraindications
Hypersensitivity to Bevacizumab or any component of the formulation

Prescription/OTC
Prescription Only

Packing Type
Vial

Compatibility
For use with compatible IV solutions

Strength
400 mg

Administration Route
Intravenous (IV) Infusion Only

Container Material
Glass Vial

Indication
Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Other Solid Tumors

Brand Name
Bryxta

Bryxta 400 Mg Injection Trade Information

Minimum Order Quantity
100 Packs

FOB Port
AHMEDABAD

Payment Terms
Paypal, Cash Advance (CA), Cash in Advance (CID), Letter of Credit at Sight (Sight L/C), Letter of Credit (L/C)

Delivery Time
3 Days

Sample Policy
Sample costs shipping and taxes has to be paid by the buyer

Packaging Details
Box

Main Export Market(s)
Asia, Australia, Central America, North America, South America, Eastern Europe, Western Europe, Middle East, Africa

Main Domestic Market
All India

About Bryxta 400 Mg Injection

Bryxta 400 mg Injection contains Bruton's Tyrosine Kinase (BTK) Inhibitor known as Ibrutinib. It is a targeted therapy used in the treatment of certain types of cancer, particularly blood cancers.

Key Uses:

Chronic Lymphocytic Leukemia (CLL): Ibrutinib is commonly used to treat Chronic Lymphocytic Leukemia (CLL), a type of cancer that affects the white blood cells called B-cells.
Mantle Cell Lymphoma (MCL): It is also approved for the treatment of Mantle Cell Lymphoma, an aggressive form of non-Hodgkin lymphoma.
Waldenstrms Macroglobulinemia: Bryxta is used to treat Waldenstrms macroglobulinemia, a rare type of non-Hodgkin lymphoma that involves B-cells.
Other B-cell Malignancies: Bryxta may be used to treat other B-cell related cancers like Chronic Graft-versus-Host Disease (cGVHD) after stem cell transplants.

Mechanism of Action:

Ibrutinib works by inhibiting Bruton's Tyrosine Kinase (BTK), an enzyme that plays a crucial role in the signaling pathways of B-cells. BTK is involved in the activation of B-cells, which are critical for the growth and survival of many blood cancers. By inhibiting BTK, Ibrutinib blocks the signals that promote the growth and survival of these cancerous cells, leading to tumor shrinkage and cell death.

Common Side Effects:

Fatigue or weakness.
Diarrhea.
Nausea.
Bruising or bleeding more easily.
Infections: Since Ibrutinib can lower the ability of the immune system to fight infections, there is an increased risk of infections.
Rash or skin reactions.

Serious Side Effects:

Heart Problems: Ibrutinib can cause arrhythmias or irregular heartbeats. Patients with existing heart problems should be monitored carefully.
Bleeding: Ibrutinib can increase the risk of severe bleeding, including internal bleeding or major bruising.
Infections: Due to its effect on the immune system, Ibrutinib may increase the risk of serious infections, such as pneumonia or fungal infections.
Liver Toxicity: Liver problems (including elevated liver enzymes) can occur, requiring monitoring of liver function during treatment.
High Blood Pressure: Ibrutinib can cause high blood pressure (hypertension), which should be managed during treatment.

Dosage:

The typical dose of Bryxta 400 mg will depend on the condition being treated and the patient's individual response. It is usually administered as a single oral dose, but the 400 mg dose is generally given once daily.

Administration:

Bryxta is administered via intravenous (IV) infusion. It is typically given in a clinical setting, with the administration taking place over a period of time, depending on the dose and the patient's needs.

Precautions:

Heart and Blood Pressure: Patients should be monitored for heart issues or high blood pressure, as Ibrutinib can cause arrhythmias and elevated blood pressure.
Infection Risk: Ibrutinib weakens the immune system, so precautions should be taken to prevent infections.
Liver Function: Regular monitoring of liver function tests is necessary as liver toxicity can occur.
Bleeding Risk: Patients should be monitored for signs of bleeding, such as unusual bruising, blood in the urine, or excessive bleeding during minor cuts or injuries.
Pregnancy: Ibrutinib is contraindicated during pregnancy and breastfeeding due to potential harm to the fetus or infant. Women of childbearing age should use reliable contraception during treatment.

Summary:

Bryxta 400 mg Injection contains Ibrutinib, a Bruton's Tyrosine Kinase (BTK) inhibitor, used to treat Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and other B-cell related cancers. It works by blocking a key enzyme in B-cells, which slows or stops the growth of cancerous cells. Side effects include fatigue, diarrhea, and an increased risk of infections, bleeding, and heart problems. Regular monitoring of liver function, blood pressure, and signs of bleeding is essential during treatment. Ibrutinib should not be used in pregnant women and requires careful management to prevent serious side effects.